InMed Soars 100% on $290M Migraine Deal
InMed Pharmaceuticals shares jumped 108.6% to $1.42 after agreeing to merge with Mentari Therapeutics in an all-stock deal, shifting focus to migraine prevention. The combined company will operate as Mentari, backed by a $290 million private placement, with InMed shareholders owning about 1.51%. Nearly 69.6 million shares traded, and InMed’s market value reached $5.7 million.